Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers

This study has been completed.
Information provided by:
National Institutes of Health Clinical Center (CC) Identifier:
First received: June 19, 2007
Last updated: May 14, 2010
Last verified: April 2010

This study will test the safety and effectiveness of two vaccines on slowing disease progression, improving blood counts, reducing the need for transfusions of blood and platelets, or achieving remission in patients with myelodysplastic syndrome (MDS, also known as myelodysplasia), acute myeloid leukemia (AML) or chronic myeloid leukemia (CML). The vaccines consist of peptides (parts of proteins) found in MDS, AML and CML stem cells, combined with a substance called MontanideTM. They are administered with GM-CSF. The Montanide and the GM-CSF help the immune system respond to the vaccines.

People 18 years of age or older with MDS, AML or CML may be eligible for this study.

Participants receive six injections of the vaccines, one dose every other week for a total of 10 weeks. The injections are given in the upper arm, upper leg, or abdomen. A separate injection of GM-CSF is given in the same area as the vaccine injections. Subjects are observed for 2 hours after the first vaccination and at least 30 minutes after each subsequent vaccination for allergic reactions. In addition to the vaccination, subjects undergo the following:

  • History and physical exam, chest x-ray, blood tests and bone marrow aspirate and biopsy before starting the vaccinations.
  • Safety monitoring during vaccine administration (every other week for 10 weeks) with blood tests and check of vital signs.
  • Follow-up safety monitoring (weeks 12 and 16) with blood tests every visit, chest x-ray at week 12 and bone marrow biopsy visit 16.

Condition Intervention Phase
Myelodysplastic Syndrome (MDS)
Acute Myeloid Leukemia (AML)
Chronic Myeloid Leukemia (CML)
Biological: WT1:126-134 Peptide
Biological: PR1:169-177 Peptide
Drug: WT1 and PR1 Peptide Vaccines
Drug: GM-CSF (Sargramostim)
Biological: WT1 and PR1 Peptide Vaccines
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Efficacy of WT1 and PRI Peptide Vaccination for Patients With Low Risk Myeloid Malignancies

Resource links provided by NLM:

Further study details as provided by National Institutes of Health Clinical Center (CC):

Primary Outcome Measures:
  • The efficacy and toxicity associated with 6 doses of a combination of WT-1:126-134 and PR1:169-177 peptide vaccines in selected patients with myeloid malignancies. [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Changes in marrow blast cells, blood counts, transfusion dependence, time to disease progression, survival and response to booster vaccination. [ Designated as safety issue: Yes ]

Enrollment: 10
Study Start Date: June 2007
Study Completion Date: April 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Biological: WT1:126-134 Peptide
    Biological: PR1:169-177 Peptide
    Drug: WT1 and PR1 Peptide Vaccines
    Drug: GM-CSF (Sargramostim)
    Biological: WT1 and PR1 Peptide Vaccines
Detailed Description:

Leukemias and the related disorders myelodysplastic syndrome and myeloproliferative diseases represent a wide group of bone marrow stem cell malignancies. Some patients can be cured with chemotherapy or by allogeneic stem cell transplantation. However standard treatment approaches are not effective for patients who become refractory to chemotherapy, those who relapse after transplantation and those with progressive disease. The management of such patients remains unsatisfactory and requires new treatment approaches other than chemotherapy.

The immunological graft-versus-leukemia (GVL) effect seen after allogeneic stem cell transplantation suggests that stimulating the patient's own T cell responses to MDS and leukemia with a vaccine might also retard disease progression and even achieve disease remissions. WT1 and PR1 were identified as target antigens because both antigens are highly expressed by CD34 plus stem cells of most patients with myeloid malignancies but not by normal marrow cells. An immunotherapeutic approach to vaccinate against PR1 and WT1 antigens could induce T cell response against MDS and leukemic cells while sparing normal cells and by using a combination of two antigens the risk of disease escape by antigen down regulation should be further diminished. Indeed in a safety study of one dose of a combination of PRl and WT1 vaccination, we demonstrated that immunological response against one or both vaccines could be induced in all subjects who were vaccinated. This immunological response was associated with a transient reduction in the leukemia burden. Furthermore the vaccine combination was well tolerated.

Therefore we propose this Phase II trial, the third in a series of planned peptide vaccine research protocols, which will evaluate the safety and efficacy associated with an immunotherapy approach using two peptide vaccines, namely PR 1 : 169- 177 and WT-1: 126-1 34 in Montanide adjuvant, administered concomitantly with GM-CSF (Sargramostim), every 2 weeks for 10 weeks (6 doses WT1 plus 6 doses PRl plus GM-CSF) in select patients diagnosed with MDS, AML or CML. Subjects with immunological response to one or both peptide vaccines will have the option of receiving an additional 6 boosters of the WT-1:126-135 and PR1:169-177 peptide vaccines at 3 monthly intervals.

The primary objective will be to evaluate the efficacy and toxicity associated with 6 doses of a combination of WT-1: 126-134 and PRl: 169-177 peptide vaccines in Montanide adjuvant administered concomitantly with GMCSF (Sargramostim) in selected patients with myeloid malignancies (MDS, AML, CML).

The primary endpoint will be immune response (studying changes in the frequencies of circulating PR1 and WT1 specific T cells) which will serves as a surrogate for evaluating for the efficacy of the study.

Secondary Endpoints will include changes in marrow blast cells, blood counts, transfusion dependence, time to disease progression and survival.


Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Diagnosed with MDS (B subtypes RA, RARS -Low Risk) (MDS with 5q- must have failed lenalidomide or been ineligible to receive it)


Diagnosed with AML and in complete remission within 5 years of treatment with less than 5% marrow blasts


Diagnosed with CML in chronic phase

Unsuitable for stem cell transplantation (age over sixty or unavailability of a fully-matched donor)


made an informed decision not to undergo the transplant procedure


are between 6 months 3 years following allogeneic SCT and fulfill the following criteria:

100% donor engraftment,

Less than 5% blasts in marrow

normal marrow cellularity

HLA-A020 1 positive at one allele

Ages 18-85 years old

Off all lymphoablative chemotherapeutic agents


  • Hypoplastic MDS
  • Relapsed AML
  • CML in accelerated phase or blast crisis
  • Hypocellular bone marrow (less than 20%)
  • History of Wegener's granulomatosis
  • Serologic antibody against proteinase-3 (ANCA positive)
  • Previous allergic reaction to Montanide Adjuvant
  • Positive test for HIV
  • Treatment with systemic corticosteroids or immunosuppresants within 14 days prior to study entry
  • Comorbidity of such severity that it would preclude the patient's ability to tolerate protocol therapy
  • Predicted survival less than 28 days
  • Pregnant or breast feeding (All female patients must have a urine pregnancy test within 1 week prior to vaccine administration)
  • Unwilling to practice abstinence or effective contraception (men and women) during the study period.
  • Enrolled in another drug or vaccine clinical trial during the study period
  • Inability to comprehend the investigational nature of the study and provide informed consent
  Contacts and Locations
Please refer to this study by its identifier: NCT00488592

United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
  More Information

Additional Information:
Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: A. John Barrett, M.D./National Heart, Lung, and Blood Institute, National Institutes of Health Identifier: NCT00488592     History of Changes
Obsolete Identifiers: NCT00499772
Other Study ID Numbers: 070159, 07-H-0159
Study First Received: June 19, 2007
Last Updated: May 14, 2010
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Myelodyplastic Syndrome (MDS)
Acute Myeloid Leukemia (AML)
Chronic Myeloid Leukemia (CML)
Wilm's Tumor-1
Myelodysplastic Syndrome
Acute Myeloid Leukemia
Chronic Myeloid Leukemia

Additional relevant MeSH terms:
Leukemia, Myeloid, Acute
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Myelodysplastic Syndromes
Neoplasms by Histologic Type
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions processed this record on April 21, 2014